Collegium Pharmaceutical (COLL) shares rose by nearly 13% in recent trading on Wednesday after the company provided 2025 guidance.
Collegium said it expects 2025 product revenue of between $735 million to $750 million. Analysts polled by FactSet expect $739.9 million.
Jornay PM, an attention-deficit/hyperactivity disorder drug, is positioned to be the lead growth driver, with expected net revenue of more than $135 million in 2025, Collegium said.
Price: 32.82, Change: +3.68, Percent Change: +12.63
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。